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Abstract In combination with equimolar 1,2-dioleoyl-L-K-glyc-
ero-3-phosphatidyl ethanolamine, a novel cholesterol-based cat-
ionic lipid with L-alanine head-group (2) has been demonstrated
to be strikingly more e⁄cacious (10^24-fold) in transfecting
CHO, COS-1 and HepG2 cells than its glycine analog (1)
containing just one less methylene unit in its head-group region.
Syntheses, characterizations and in vitro transfection biology of
lipids 1 and 2 are described. Present ¢ndings demonstrate that
even truly minor structural alterations, such as inclusion of just
one additional methylene functionality in the polar head-group
region, can convert an essentially transfection-incompetent cho-
lesterol-based cationic amphiphile to a remarkably e⁄cient cat-
ionic transfection lipid.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Gene therapy is becoming increasingly important as a ther-
apeutic modality to combat myriads of inherited diseases,
dreadful viral infections and cancer. Designing safe and e⁄-
cient carriers of therapeutic genes into body cells is one of the
key challenges to ensure clinical success of gene therapy [1^3].
Recombinant retroviral vectors, one of the most powerful
viral transfection vectors used for clinical applications in
gene therapy, are remarkably e⁄cient in transfecting body
cells [4,5]. However, despite wide exploitation of retroviral
gene transfer in many gene therapy trials, an alarming number
of biosafety concerns and risks associated with the use of
retroviral vectors are impeding their clinical success. Retrovi-
ral vectors, although generally replication-incompetent, are
capable of: generating replication-competent virus through
recombination events with the host genome; inducing in£am-
matory and adverse immunogenic responses against the struc-
tural components; producing insertional mutagenesis through
random integration into the host genome etc. [6^9]. Addition-
al major disadvantages of using viral vectors include their
incapability of transfecting non-dividing cells, limited insert
size and di⁄culty of large-scale production [4^9]. Conversely,
because of their very low immunogenic nature, robust manu-
facture, ability to deliver large pieces of DNA, and ease of
handling and preparation techniques, cationic liposomes are
increasingly becoming the alternative non-viral vectors of
choice in gene therapy [10^18].
One of the key parameters dictating DNA transfection e⁄-
ciency in liposomal gene delivery is the molecular structure of
the cationic lipid. Three major structural components of cat-
ionic transfection lipids (also known as cytofectins) include: a
hydrophilic polar head-group region; a hydrophobic non-po-
lar tail region consisting of either two long aliphatic hydro-
carbon chains or a cholesterol unit and a small linker func-
tionality connecting the hydrophobic tail and hydrophilic
head-groups [19]. Investigations aimed at probing the role of
each of these three structural components in modulating gene
transfer e⁄cacies of cytofectins [20^23] including our own
[24^27] continue to be an intensively pursued area of research
in non-viral gene delivery. Herein, we report on the syntheses,
characterization and the phenomenally contrasting DNA
transfection e⁄cacies of two novel lipids namely, 2-(N-glyci-
nyl)aminoethyl-cholesteryl ether (lipid 1, Fig. 1) and 2-(N-L-
alaninyl)aminoethyl-cholesteryl ether (lipid 2, Fig. 1) bearing
the same cholesterol hydrophobic skeleton, the same amide
linker and di¡ering by only one methylene unit in their polar
head-group region. As delineated below, our present ¢ndings
demonstrate that even truly minor structural alterations, such
as inclusion of an additional single methylene functionality in
the head-group region, can strikingly convert an essentially
transfection-incompetent cholesterol-based cationic amphi-
phile to a remarkably e⁄cient cationic transfection lipid.
2. Materials and methods
2.1. Materials
Amberlyst A-26 was purchased from Lancaster (Morecambe, UK).
Carbonyl diimidazole (CDI), N,N-dimethylethylenediamine and cho-
lesterol chloroformate were procured from Fluka, Switzerland. Col-
umn chromatography was performed with silica gel (Acme Synthetic
Chemicals, India, 60^120 mesh). Cell culture media, fetal bovine se-
rum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT), polyethylene glycol 8000, o-nitrophenyl-L-D-galactopyr-
anoside (ONPG), L-galactosidase enzyme and 1,2-dioleoyl-L-K-
glycero-3-phosphatidyl ethanolamine (DOPE) were purchased from
Sigma (St. Louis, MO, USA). NP40, antibiotics and agarose were
purchased from Hi-media, India. DC-Chol was synthesized as re-
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ported previously [16]. Unless otherwise stated all the other reagents
purchased from local commercial suppliers were of analytical grade
and were used without further puri¢cation. 1H nuclear magnetic res-
onance (NMR) spectra were recorded on a Varian FT 200 MHz, AV
300 MHz or Varian Unity 400 MHz. The FABMS analyses were
performed on a Micromass AUTOSPEC-M mass spectrometer (Man-
chester, UK) with OPUS V3, 1U data system. Data were acquired by
liquid secondary ion mass spectrometry (LSIMS) using meta-nitro-
benzyl alcohol as the matrix.
2.2. Syntheses
The synthetic procedures for preparing lipids 1 and 2 are depicted
schematically in Fig. 1. Detailed experimental procedures are de-
lineated below for lipid 2 as a representative example. Lipid 1 was
synthesized following essentially the same procedure.
Step a: Synthesis of N-BOC-L-alanine-cholesteryl ethylamide (II,
Fig. 1). N-BOC-L-alanine (88 mg, 0.47 mmol) was dissolved in dry
dichloromethane (DCM, 1 ml) in a two-necked 25 ml round-bottomed
£ask under nitrogen atmosphere and CDI (76 mg, 0.47 mmol) dis-
solved in dry DCM (1 ml) was added dropwise. After stirring the
reaction mixture at room temperature for 3 h, 2-aminoethyl choles-
teryl ether, I (200 mg, 0.47 mmol, a readily available cholesterol de-
rivative in our laboratory prepared conventionally from the corre-
sponding primary alcohol in three steps) dissolved in dry DCM (2
ml) was added and stirring was continued at room temperature for
19 h. Column chromatographic puri¢cation (using 60^120 mesh size
silica and 15^20% v/v acetone in hexane as the eluent) of the residue
a¡orded lipid 2 as a white solid (259 mg, 93%, Rf = 0.4, 1:4 v/v,
acetone:hexane).
1H NMR (N-BOC-L-alanine-cholesteryl ethylamide, lipid 2, 200
MHz, CDCl3): N=0.60^2.30 [m, 43H, cholesteryl skeleton], 1.40 [s,
9H, (CH3)3COCONH-], 2.35 [t, 2H, BOC-NH-CH2-CH2-CO-], 3.10
[m, 1H, H3K(Chol)], 3.30^3.75 [m, 6H, -CO-NH-CH2-CH2-O-+BOC-
NH-CH2-CH2-CO-], 5.15 [bs, 1H, BOC-NH-CH2-CH2-CO-], 5.30 [m,
1H, H6(Chol)], 5.95 [brs, 1H, -CONH-CH2-CH2-].
1H NMR (N-BOC-glycine-cholesteryl ethylamide, lipid 1, 300 MHz,
CDCl3): N=0.60^2.35 [m, 43H, cholesteryl skeleton], 1.40 [s, 9H,
(CH3)3COCONH-], 3.15 [m, 1H, H3K(Chol)], 3.40^3.60 [m, 4H,
-CO-NH-CH2-CH2-O-], 3.85 [d, 2H, BOC-NH-CH2-CO-], 5.10 [bs,
1H, BOC-NH-], 5.40 [m, 1H, H6(Chol)], 6.40 [brs, 1H, -CONH-
CH2-CH2-].
Steps b and c. N-BOC-L-alanine-cholesteryl ethylamide, II (inter-
mediate product obtained from step a, 170 mg, 0.28 mmol) was taken
in a 25 ml round-bottomed £ask and dissolved in 1.30 ml of tri£uoro-
acetic acid (TFA):DCM (1:4, v/v). After stirring the reaction at room
temperature for 70 min, the TFA^DCM mixture was completely re-
moved with a stream of nitrogen gas. Column chromatographic pu-
ri¢cation of the residue (using 60^120 mesh size silica and 7^8% v/v
methanol in chloroform as the eluent) followed by chloride ion ex-
change in Amberlyst A-26 using methanol as the eluent a¡orded lipid
2 as a white solid (140 mg, 92%, Rf = 0.3, 10% v/v methanol in chlo-
roform).
1H NMR (lipid 2, 300 MHz, CDCl3): N=0.60^2.40 [m, 43H, cho-
lesteryl skeleton], 2.85 [bs, 2H, þNH3-CH2-CH2-CO-], 3.15 [m, 1H,
H3K(Chol)], 3.30^3.85 [m, 6H, -NH-CH2-CH2-O-+þNH3-CH2-CH2-
CO-], 5.30 [s, 1H, H6(Chol)], 7.80^8.10 [brs, 4H, -CONH-CH2-CH2-
+þNH3-CH2-CH2-CO-].
FABMS (LSIMS): m/z : 501 [Mþ] for C32H57N2O2.
1H NMR (lipid 1, 300 MHz, CDCl3): N=0.60^2.40 [m, 43H, cho-
lesteryl skeleton], 3.15 [m, 1H, H3K(Chol)], 3.30^3.60 [m, 4H, -NH-
CH2-CH2-O-], 4.00 [brs, 2H, þNH3-CH2-CO-], 5.30 [s, 1H, H6(Chol)],
8.55 [brs, 1H, -CONH-CH2-CH2-].
FABMS (LSIMS): m/z : 487 [Mþ] for C31H55N2O2.
2.3. Cells and cell culture
CHO (Chinese hamster ovary), COS-1 (SV 40 transformed African
green monkey kidney cells) and HepG2 (human hepatocarcinoma) cell
lines were procured from the National Centre for Cell Sciences
(NCCS), Pune, India. Cells were cultured at 37‡C in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM) with 10% FBS, 50 Wg/ml penicillin, 50
Wg/ml streptomycin and 20 Wg/ml kanamycin in a humidi¢ed atmo-
sphere containing 5% CO2.
2.4. Preparation of plasmid DNA
pCMV-SPORT-L-gal plasmid was a generous gift from Dr. Nalam
Madhusudhana Rao (Centre for Cellular and Molecular Biology, Hy-
derabad, India). Plasmid was ampli¢ed in Escherichia coli DH5K,
isolated by alkaline lysis and ¢nally puri¢ed by PEG-8000 precipita-
tion as described previously [28]. The purity of plasmid was checked
by the A260/A280 ratio (around 1.9) and 1% agarose gel electrophore-
sis.
2.5. Preparation of liposome
Cationic lipids (1 and 2) and DOPE (at 1:1 molar ratio) dissolved
in chloroform were dried under a stream of nitrogen gas, vacuum
desiccated for a minimum period of 4 h and hydrated in HEPES
bu¡er pH 7.4 overnight at a ¢nal cationic lipid concentration of
1 mM. The hydrated lipid ¢lms were vortexed and then sonicated
to clarity using a Ti-probe sonicator. Liposomes of DC-Chol were
prepared by the ethanol injection method. Brie£y, 70 Wl of an etha-
nolic solution of DC-Chol and DOPE (at 3:2 molar ratio) was rapidly
injected into 930 Wl of HEPES bu¡er, pH 7.4 under vortexing to give
a ¢nal cationic lipid concentration of 1 mM.
2.6. Transfection procedure
Cells were seeded at a density of 20 000 cells/well (for CHO and
HepG2) or 15 000 cells/well (for COS-1) in a 96 well plate usually 18^
24 h before transfection. 0.30 Wg of plasmid DNA (diluted to 50 Wl
with plain DMEM) was complexed with varying amounts of cationic
liposomes (diluted to 50 Wl with plain DMEM) for 15^30 min. The
molar ratios (lipid:DNA) were varied from 0.5:1 to 8:1. Cells were
washed twice with phosphate-bu¡ered saline (PBS), pH 7.40 (100 Wl
each) and the lipid:DNA complex was added to the cells. After in-
cubation for 3 h in a humidi¢ed atmosphere containing 5% CO2 at
37‡C, 100 Wl of DMEM containing 20% FBS was added to the cells.
The medium was changed to complete medium containing 10% FBS
after 24 h and the reporter gene activity was assayed after 48 h. Cells
were washed once with PBS bu¡er, pH 7.40 (100 Wl) and lysed with 50
Wl of lysis bu¡er (0.25 M Tris^HCl, pH 8.0 and 0.5% NP40). The L-
galactosidase activity per well was estimated by adding 50 Wl of
2Usubstrate solution (1.33 mg/ml of ONPG, 0.2 M sodium phos-
phate, pH 7.30 and 2 mM magnesium chloride) to the cell lysate in
a 96 well plate. Absorption of the product ortho-nitrophenol at 405
nm was converted to absolute L-galactosidase units using a calibration
curve constructed with pure (commercial) L-galactosidase enzyme.
The transfection values reported are the average values of two repli-
cate experiments performed in the same plate on the same day. Each
transfection experiment was performed three times on three di¡erent
days. The day to day variation in transfection e⁄ciency was mostly
within two- to three-fold and was dependent on the cell density and
condition of the cells.
2.7. X-gal staining
Cells expressing L-galactosidase were histochemically stained with
the substrate 5-bromo-4-chloro-3-indolyl-L-D-galactopyranoside (X-
gal) as described previously [29]. Brie£y, 48 h after transfection with
lipoplexes in 96 well plates, the cells were washed two times (2U100
Wl) with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM
KH2PO4, pH 7.4) and ¢xed with 0.5% glutaraldehyde in PBS (225 Wl).
After 15 min incubation at room temperature, the cells were washed
again with PBS three times (3U250 Wl) and subsequently stained with
1.0 mg/ml X-gal in PBS containing 5.0 mM K3[Fe(CN)6], and 5.0 mM
K4[Fe(CN)6] and 1 mM MgSO4 for 2^4 h at 37‡C. Blue colored cells
were identi¢ed by light microscope (Leica, Germany). A minimum of
100 cells were counted to determine the percentage of cells expressing
L-galactosidase.
2.8. Cell viability assay
Cytotoxicity of the cationic lipids was assessed using the MTT
reduction assay as described earlier [30]. The cytotoxicity assay was
performed in 96 well plates by maintaining the ratio of number of
cells to amount of cationic lipid constant as in transfection experi-
ments. Brie£y, 3 h after the addition of lipoplexes, MTT (5 mg/ml
PBS) was added to cells and incubated for 3^4 h at 37‡C in a CO2
incubator. Results are expressed as percent viability = [A550(treated
cells)3background]/[A550(untreated cells)3background]U100.
2.9. Size and surface charge measurements
The sizes and the global surface charges (j potentials) of liposomes
and lipoplexes in HEPES bu¡er, pH 7.4, or plain DMEM were mea-
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sured by photon correlation spectroscopy and electrophoretic mobility
with a Zetasizer 3000HSA (Malvern Instruments, UK). The system
was calibrated using the 199S6 nm Nanosphere1 Size Standard
(Duke Scienti¢c, Palo Alto, CA, USA) and DTS 0050 standard
from Malvern.
3. Results and discussion
Fig. 2A^C summarizes the e⁄cacies of lipids 1 and 2 (used
as cationic liposomes prepared in combination with an equi-
molar amount of DOPE as co-lipid) in transfecting CHO,
COS-1 and HepG2 cells across the increasing lipid:DNA mo-
lar ratios 0.5:1.0^8.0:1.0 (using pCMV-SPORT-L-gal plasmid
as the reporter gene). Although lipids 1 and 2 structurally
di¡er from each other by only one CH2 unit in the head-
group region (all the other structural components being ex-
actly the same), the in vitro gene delivery e⁄cacies of lipid 2
were found to be strikingly superior to those of lipid 1 in all
three cell lines (Fig. 2A^C). While the transfection e⁄ciencies
of lipid 2 at lipid:DNA molar ratios of 2:1 or 1:1 were com-
parable to or better than those of DC-Chol (one of the most
popular, easy-to-synthesize and extensively used cholesterol-
based cationic transfection lipids in liposomal gene delivery),
lipid 1 was found to be about 10^24-fold less e⁄cient (essen-
tially transfection-ine⁄cient) in transfecting all three cell lines
(Fig. 2A^C). In addition, with a view to measuring the rela-
tive percentage pro¢les of the transfected cells for lipids 1, 2
and DC-Chol, the representative CHO cells were histochemi-
cally stained with X-gal after 48 h of transfection using the
optimal lipid:DNA molar ratio of 2:1. Such histochemical
staining of whole cells showed that the percentages of trans-
fected CHO cells with lipid 2 were signi¢cantly higher than
those with lipids 1 and DC-Chol (Fig. 3), a result consistent
with the relative transfection e⁄cacy pro¢les of these lipids
obtained by quantitative estimation of the expressed L-galac-
tosidase (Fig. 2A^C).
Interestingly, while lipid 2 showed markedly higher trans-
fection e⁄cacies than lipid 1 in all three cell lines, the relative
transfection properties of lipid 2 and DC-Chol were found to
be cell-dependent (Fig. 2A^C). The origin of such cell-depen-
dent relative transfection pro¢les of lipid 2 and DC-Chol re-
mains elusive at this point of investigation. The overall trans-
fection e⁄ciencies of both lipids 2 and DC-Chol in COS-1 and
CHO cells were observed to be signi¢cantly higher than those
in HepG2 cells (Fig. 2A^C). Such relatively weak transfection
behavior of lipid 2 and DC-Chol in HepG2 cells may partly
originate from the lower cell proliferating rate of HepG2 cells
compared to that of COS-1 and CHO cells. Taken together,
the relative transfection properties of lipids 1 and 2 in COS-1,
CHO and HepG2 cells summarized in Fig. 2A^C convincingly
demonstrate that even truly minor structural variations are
also capable of adversely impeding the gene delivery e⁄cacies
of cholesterol-based cationic transfection lipids.
With a view to gaining insight into whether the phenomen-
ally di¡erent in vitro DNA transfection properties of lipids 1
and 2 were due to their varying inherent toxicity pro¢les,
MTT-based cell viability assays were performed in HepG2
cells across the entire range of lipid:DNA molar ratios used
Fig. 1. Synthesis of lipids 1 and 2.
Table 1
Sizes and j potentials of liposomes and lipoplexesa
Lipid Lipid:DNA (molar ratio)
1:0 0.5:1 1:1 2:1 4:1 8:1
Size (nm)
1 231S 2.1 705.2S 29.1 654.8S 24.8 733.3S 23.8 940.7S 10.7 1000.6S 21.8
2 116.3S 3.1 518.7S 12.6 373.7S 3.7 446.6S 15.5 690.9S 7.4 1638.6S 133.5
Zeta potential (mV)
1 28.7S 2.2 334.8S 1.3 332.5S 1.1 333.8S 1.1 333.3S 1 332.9S 0.8
2 22.8S 3.2 336.7S 0.8 336.5S 0.6 336.4S 0.8 333.4S 1 323.6S 2
aSizes and j potentials of liposomes and lipoplexes (in HEPES bu¡er, pH 7.40 and plain DMEM, respectively) were measured by laser light
scattering using a Zetasizer 3000A (Malvern Instruments, UK). Values shown are the averages of three (for size) and 10 measurements (for j
potential).
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in the actual transfection experiments. Cell viabilities of both
lipid 1 and 2 were found to be remarkably high (s 80% cell
viability) up to a lipid:DNA charge ratio of 4:1 (Fig. 4).
Thus, the contrasting transfection behaviors of lipids 1 and
2 (Fig. 2) are unlikely to originate from varying cell cytotox-
icities of the lipids. With a view to probing the role of sizes
and global surface charges of the lipoplexes (if any) in mod-
ulating the transfection properties of lipids 1 and 2, we next
measured the j potentials and particle sizes of the lipoplexes
made from lipids 1 and 2 across the varying lipid:DNA molar
ratios in the presence of DMEM using a dynamic laser light
scattering instrument equipped with j-sizing capacity. Inter-
estingly, j potentials of the lipoplexes prepared from both
lipid 1 and 2 were found to remain essentially unchanged
around 330 to 335 mV as the lipid:DNA charge ratios
were increased from 0.5:1 to 4:1 (Table 1). Thus, the surface
potential characteristics summarized in Table 1 convincingly
demonstrate that the lipoplex global surface charge is unlikely
to play any dominant role in in£uencing transfection e⁄cacies
of the presently described cholesterol-based cationic lipids.
Surprisingly, both liposomes and lipoplexes prepared from
lipid 2 having the additional methylene unit in its head-group
region were measured to be about 1.5^2.0-fold smaller than
those prepared from lipid 1 (Table 1). Thus, relatively poor
endocytotic cellular uptake of these larger lipoplexes of lipid 1
Fig. 2. A^C: Transfection e⁄ciencies of cationic lipids 1, 2 and
DC-Chol in CHO (A), COS-1 (B) and HepG2 (C) cells. The L-ga-
lactosidase activities in each well was converted to absolute L-galac-
tosidase milliunits using a standard curve obtained with pure (com-
mercial) L-galactosidase. All the lipids were tested on the same day
and the data shown are the average value of two replicate experi-
ments performed on the same day (n=2). Each transfection experi-
ment was performed three times on three di¡erent days.
Fig. 3. Histochemical X-gal staining of transfected CHO cells with
lipids 1, 2 and DC-Chol at a lipid:DNA molar ratio of 2:1. Cells
expressing L-galactosidase were stained with X-gal as described in
the text. A minimum of 100 cells were counted to estimate the per-
cent of cells transfected. The values shown are averages of two inde-
pendent measurements.
Fig. 4. Representative cell viabilities of cationic lipids 1 and 2 in
HepG2 cells using the MTT-based assay. The toxicity assays were
performed as described in the text. The data presented are average
values of duplicate experiments (n=2). Results were expressed as
% viability= [A550(treated cells)3background]/[A550(untreated cells)3
background]U100.
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(650^950 nm, Table 1) could be one of the impeding param-
eters responsible for making lipid 1 essentially transfection-
incompetent. However, why liposomes and lipoplexes of lipid
2 with one extra methylene unit in its molecular structure are
smaller than those of lipid 1 remains an open question at this
point of the investigation.
In summary, the present ¢ndings demonstrate that even
truly minor structural modi¢cation, such as inclusion of an
additional single methylene unit in the head-group region, can
impart remarkable gene transfer property to an essentially
transfection-incompetent cholesterol-based cationic lipid.
High DNA transfection e⁄cacies of lipid 2 in multiple cells
will now provide the impetus for undertaking detailed struc-
ture^activity studies involving libraries of cholesterol-based
cationic lipids with L-alanine analogs in their head-group re-
gions.
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